TN2009000451A1 - Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor - Google Patents

Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Info

Publication number: TN2009000451A1
Authority: TN; Tunisia
Prior art keywords: reversible; intrvenous; inhibitor; acting; direct
Prior art date: 2007-05-02

Application number

TNP2009000451A

Other languages

English (en)

Inventor

Robert M Scarborough

Daniel D Gretler

Pamela B Conley

Patrick Andre

Athiwat Hutchaleelaha

David R Phillips

Anjali Pandey

Huang Wolin

Original Assignee

Portola Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-02

Filing date

2009-10-30

Publication date

2011-03-31

2009-10-30 Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc

2011-03-31 Publication of TN2009000451A1 publication Critical patent/TN2009000451A1/fr

Links

239000002172 P2Y12 inhibitor Substances 0.000 title 1
230000002441 reversible effect Effects 0.000 title 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003527 fibrinolytic agent Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000006965 reversible inhibition Effects 0.000 abstract 1
208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
229960000103 thrombolytic agent Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2009000451A 2007-05-02 2009-10-30 Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor TN2009000451A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US91564907P	2007-05-02	2007-05-02
US94792107P	2007-07-03	2007-07-03
PCT/US2008/062518 WO2008137753A2 (fr)	2007-05-02	2008-05-02	Dosage oral et intraveineux de l'inhibiteur p2y12 réversible et à action directe

Publications (1)

Publication Number	Publication Date
TN2009000451A1 true TN2009000451A1 (en)	2011-03-31

Family

ID=39587015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000451A TN2009000451A1 (en)	2007-05-02	2009-10-30	Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Country Status (17)

Country	Link
US (2)	US20090048216A1 (fr)
EP (1)	EP2079464A2 (fr)
JP (1)	JP2010526101A (fr)
KR (1)	KR20100029746A (fr)
CN (1)	CN101795682A (fr)
AU (1)	AU2008247483A1 (fr)
BR (1)	BRPI0811476A2 (fr)
CA (1)	CA2686203A1 (fr)
CO (1)	CO6241104A2 (fr)
EA (1)	EA200901473A1 (fr)
EC (1)	ECSP099778A (fr)
GT (1)	GT200900284A (fr)
IL (1)	IL201834A0 (fr)
MA (1)	MA31663B1 (fr)
MX (1)	MX2009011843A (fr)
TN (1)	TN2009000451A1 (fr)
WO (1)	WO2008137753A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101300013B (zh) *	2005-11-03	2012-11-28	博尔托拉制药公司	[4-(6-卤代-7-取代的-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基磺酰脲类及与其相关的形式和方法
JP5390407B2 (ja) *	2007-03-06	2014-01-15	ノバルティスアーゲー	炎症またはアレルギー症状の処置に適する二環式有機化合物
US20090156620A1 (en) *	2007-05-02	2009-06-18	Portola Pharmaceuticals, Inc.	[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
AU2008247457A1 (en) *	2007-05-02	2008-11-13	Portola Pharmaceuticals, Inc.	[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
US9427448B2 (en) *	2009-11-11	2016-08-30	The Medicines Company	Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2010075861A2 (fr) *	2008-12-30	2010-07-08	Thrombologic Aps	Détection de patients dans un état critique présentant un risque accru de développer une défaillance viscérale et composés pour les traiter
US10376532B2 (en)	2009-11-11	2019-08-13	Chiesi Farmaceutici, S.P.A.	Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2778880C (fr)	2009-11-11	2018-02-13	The Medicines Company	Procedes de traitement ou de prevention de thrombose de stent
US8663661B2 (en) *	2009-12-23	2014-03-04	Ratiopharm Gmbh	Solid pharmaceutical dosage form of ticagrelor
EP2523657A1 (fr)	2010-01-12	2012-11-21	Portola Pharmaceuticals, Inc.	Composition pharmaceutique et forme galénique de l'élinogrel et leurs méthodes d'application
WO2011137459A1 (fr) *	2010-04-30	2011-11-03	Portola Pharmaceuticals, Inc.	Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables
WO2012072743A1 (fr) *	2010-12-01	2012-06-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédé et trousses pour déterminer la sensibilité des plaquettes à une activation dans un patient
EP2646434B1 (fr) *	2010-12-03	2019-05-15	Portola Pharmaceuticals, Inc.	Compositions pharmaceutiques, formes pharmaceutiques et nouvelles formes du composé de formule (i), et leurs procédés d'utilisation
MY205605A (en)	2017-03-15	2024-10-29	Idorsia Pharmaceuticals Ltd	Subcutaneous administration of a p2y12 receptor antagonist
MA49452A (fr)	2017-06-23	2021-05-05	Chiesi Farm Spa	Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) *	2017-08-21	2019-09-27	盐城锦明药业有限公司	一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6906063B2 (en) *	2000-02-04	2005-06-14	Portola Pharmaceuticals, Inc.	Platelet ADP receptor inhibitors
CN101300013B (zh) *	2005-11-03	2012-11-28	博尔托拉制药公司	[4-(6-卤代-7-取代的-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基磺酰脲类及与其相关的形式和方法

2008
- 2008-05-02 EP EP08747561A patent/EP2079464A2/fr not_active Withdrawn
- 2008-05-02 CA CA002686203A patent/CA2686203A1/fr not_active Abandoned
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/fr active Application Filing
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Withdrawn
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2008137753A2 (fr)	2008-11-13
CN101795682A (zh)	2010-08-04
ECSP099778A (es)	2010-01-29
BRPI0811476A2 (pt)	2014-11-04
IL201834A0 (en)	2010-06-16
MX2009011843A (es)	2010-04-22
GT200900284A (es)	2012-01-31
CO6241104A2 (es)	2011-01-20
KR20100029746A (ko)	2010-03-17
EP2079464A2 (fr)	2009-07-22
US20120009172A1 (en)	2012-01-12
WO2008137753A3 (fr)	2009-02-12
MA31663B1 (fr)	2010-09-01
US20090048216A1 (en)	2009-02-19
CA2686203A1 (fr)	2008-11-13
JP2010526101A (ja)	2010-07-29
EA200901473A1 (ru)	2010-06-30
AU2008247483A1 (en)	2008-11-13

Similar Documents

Publication	Publication Date	Title
TN2009000451A1 (en)	2011-03-31	Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
CY2023002I1 (el)	2023-06-09	Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
HK1160779A1 (en)	2012-08-17	Cdk inhibitor for the treatment of mesothelioma
IL211825A (en)	2016-08-31	Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention
MA33803B1 (fr)	2012-12-03	Inhibiteur de bromodomaine de benzodiazépine
MY140514A (en)	2009-12-31	Triazolopyridine derivatives as inhibitors of lipases and phospholipases
ECSP099376A (es)	2009-07-31	Inhibidores de la actividad de la akt
HN2009003002A (es)	2014-03-24	Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
MX2015012432A (es)	2016-02-05	Inhibidores piridinicos de la cinasa cdk9.
PL1986669T3 (pl)	2012-09-28	Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX341212B (es)	2016-08-11	Inhibidor de bromodominio de benzodiazepina.
TR201907804T4 (tr)	2019-06-21	Apaf-1 inhibitör bileşikleri.
TN2009000446A1 (en)	2011-03-31	P70 s6 kinase inhibitors
BRPI0917444A2 (pt)	2015-12-01	composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
CL2008003798A1 (es)	2009-10-09	Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
CL2013001136A1 (es)	2014-03-07	Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
MX2009014235A (es)	2010-04-27	4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
UA105036C2 (uk)	2014-04-10	Амінотетралінові похідні, фармацевтична композиція, яка їх містить, і їх застосування в терапії
MX2009004017A (es)	2009-07-24	Usos de los compuestos carboxi-amido triazol y sus sales.
MX2009011578A (es)	2009-11-11	6-fenilpirimidinonas como moduladores de pim.
PL2222294T3 (pl)	2014-09-30	Kompozycje zawierające pochodne polifenoli stylbenowych oraz ich zastosowanie do zwalczania patologii i starzenia się organizmów żywych
UA109290C2 (uk)	2015-08-10	Спільні кристали і солі інгібіторів ccr3
MA32776B1 (fr)	2011-11-01	Inhibiteurs de l'akt et de la p70 s6 kinase
UA93709C2 (ru)	2011-03-10	12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2137175A4 (fr)	2011-08-03	Nouveau composé à base de phénanthrènequinone et composition pharmaceutique contenant ce dernier utilisé pour le traitement ou la prévention du syndrome métabolique impliquant des maladies